Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis : A Danish Nationwide Cohort Study. / Schwarz, Christopher Willy; Loft, Nikolai; Rasmussen, Mads Kirchheiner; Nissen, Christoffer V.; Dam, Tomas Norman; Ajgeiy, Kawa Khaled; Egeberg, Alexander; Skov, Lone.
In: Acta Dermato-Venereologica, Vol. 101, No. 10, adv00579, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis
T2 - A Danish Nationwide Cohort Study
AU - Schwarz, Christopher Willy
AU - Loft, Nikolai
AU - Rasmussen, Mads Kirchheiner
AU - Nissen, Christoffer V.
AU - Dam, Tomas Norman
AU - Ajgeiy, Kawa Khaled
AU - Egeberg, Alexander
AU - Skov, Lone
PY - 2021
Y1 - 2021
N2 - Identifying patient characteristics associated with achieving treatment response to biologics in patients with psoriasis could prevent expensive switching between biologics. The aim of this study was to identify patient characteristics that predict the efficacy of treatment for biologics that inhibit tumour necrosis factor-α, interleukin-12/-23, and -17A. The study investigated biologic-naïve patients from the DERMBIO registry treated with adalimumab, etanercept, infliximab, secukinumab, or ustekinumab. Multivariable logistic models were conducted to assess associations between patient characteristics and treatment response. A total of 2,384 patients were included (adalimumab n = 911; etanercept n = 327; infliximab n = 152; secukinumab n = 323; ustekinumab n = 671). Smoking (odds ratio 0.74; 95% confidence interval (CI) 0.56-0.97; p = 0.03) and higher bodyweight (odds ratio 0.989; 95% CI 0.984-0.994; p < 0.001) reduced the odds of achieving response defined as Psoriasis Area and Severity Index ≤2.0 after 6 months of treatment. In conclusion, higher bodyweight and smoking were associated with a reduced probability of treatment response for tumour necrosis factor-α inhibitors, ustekinumab, and secukinumab.
AB - Identifying patient characteristics associated with achieving treatment response to biologics in patients with psoriasis could prevent expensive switching between biologics. The aim of this study was to identify patient characteristics that predict the efficacy of treatment for biologics that inhibit tumour necrosis factor-α, interleukin-12/-23, and -17A. The study investigated biologic-naïve patients from the DERMBIO registry treated with adalimumab, etanercept, infliximab, secukinumab, or ustekinumab. Multivariable logistic models were conducted to assess associations between patient characteristics and treatment response. A total of 2,384 patients were included (adalimumab n = 911; etanercept n = 327; infliximab n = 152; secukinumab n = 323; ustekinumab n = 671). Smoking (odds ratio 0.74; 95% confidence interval (CI) 0.56-0.97; p = 0.03) and higher bodyweight (odds ratio 0.989; 95% CI 0.984-0.994; p < 0.001) reduced the odds of achieving response defined as Psoriasis Area and Severity Index ≤2.0 after 6 months of treatment. In conclusion, higher bodyweight and smoking were associated with a reduced probability of treatment response for tumour necrosis factor-α inhibitors, ustekinumab, and secukinumab.
U2 - 10.2340/actadv.v101.351
DO - 10.2340/actadv.v101.351
M3 - Journal article
C2 - 34642768
AN - SCOPUS:85120924239
VL - 101
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
IS - 10
M1 - adv00579
ER -
ID: 301036727